MedTrace Logo

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00733642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-07-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.

Conditions

Interventions

BIOLOGICAL

PF-04360365 1 mg/kg

PF-04360365 1 mg/kg infused as a single dose

BIOLOGICAL

PF-04360365 3 mg/kg

PF-04360365 3 mg/kg infused as a single dose

BIOLOGICAL

PF-04360365 5 mg/kg

PF-04360365 5 mg/kg infused as a single dose

BIOLOGICAL

PF-04360365 10 mg/kg

PF-04360365 10 mg/kg infused as a single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733642 on ClinicalTrials.gov